Published in Drug Week, June 5th, 2009
Peplinís Chief Executive Officer, Tom Wiggans, is pleased with the positive results and said: ďOnce again, our team has done an excellent job of obtaining great clinical results while completing our first Phase III trial within the expected timeframe.Ē
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.